Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 1 May 2019, 08:09 HKT/SGT
Share:
    

Source: Eisai
Eisai Buys Out Purdue Rights to End Collaboration

TOKYO, May 1, 2019 - (JCN Newswire) - Eisai Co., Ltd. announces that its U.S. subsidiary Eisai Inc. has bought out Purdue Pharma L.P.'s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer Disease. Eisai group will solely conduct the development and the commercialization of lemborexant globally.

Discovered by Eisai, lemborexant is an investigational dual orexin receptor antagonist. The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for lemborexant for use in the treatment of insomnia disorders for review in March 2019 and set a Prescription Drug User Fee Act (PDUFA) date for December 27, 2019. For Japan, a marketing authorization application for lemborexant for use in the treatment of insomnia disorder has been submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) in March 2019 and is currently under review. Furthermore, a Phase II clinical study of lemborexant for ISWRD in patients with Alzheimer's Disease is ongoing.

Through lemborexant, Eisai is striving to address unmet medical needs and contribute to further increasing the benefits for patients with sleep disorders and their families.

About Lemborexant

Lemborexant is a novel investigational small molecule compound, discovered and developed by Eisai in-house scientists, that inhibits orexin signaling by binding competitively to both orexin receptor subtypes (orexin receptor 1 and 2). In individuals with normal daily sleep-wake rhythms, orexin signaling is believed to promote periods of wakefulness. In individuals with sleep-wake disorders, it is possible that orexin signaling that regulates wakefulness is not functioning normally, suggesting that inhibiting inappropriate orexin signaling may enable initiation and maintenance of sleep. Additionally, a Phase 2 clinical study of lemborexant in patients with irregular sleep-wake rhythm disorder (ISWRD) and mild to moderate Alzheimer's dementia is underway.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com

Contact:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


May 1, 2019 08:09 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Aug 1, 2019 10:41 HKT/SGT
Eisai to Refresh and Launch Sahne Cream After 20 Years with Mild Scent and New Package
July 23, 2019 11:37 HKT/SGT
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA
July 19, 2019 12:00 HKT/SGT
Eisai Presented Latest Trends of Treatment for Alzheimer's at AAIC 2019
July 19, 2019 08:15 HKT/SGT
Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019
July 18, 2019 13:26 HKT/SGT
Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019
July 18, 2019 12:01 HKT/SGT
Eisai Presents Nonclinical Research Results of Elenbecestat at AAIC 2019
July 17, 2019 08:20 HKT/SGT
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
July 11, 2019 12:59 HKT/SGT
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series
July 11, 2019 09:04 HKT/SGT
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019
July 10, 2019 12:27 HKT/SGT
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: